Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 4/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070059 | 0.86 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53RETKDM5AALDH1A1 | |
| SCHEMBL20147507 | 0.83 | RET (0.35) | SMN1; SMN2TP53RETKDM5ATSHR | |
| SCHEMBL20070146 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53RETKDM5A | |
| SCHEMBL20070370 | 0.78 | SSTR4 (0.42) | SMN1; SMN2TP53RETKDM5A | |
| SCHEMBL23551691 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2TP53KDM5AALDH1A1HPGD | |
| SCHEMBL20147533 | 0.76 | RET (0.37) | SMN1; SMN2TP53RETKDM5AALDH1A1 | |
| SCHEMBL22857063 | 0.75 | RET (0.39) | SMN1; SMN2TP53RETKDM5AALDH1A1 | |
| SCHEMBL20147984 | 0.74 | RET (0.36) | SMN1; SMN2TP53RETKDM5AALDH1A1 | |
| SCHEMBL20069720 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2TP53RETKDM5APREP | |
| SCHEMBL17361133 | 0.70 | FGFR4 (0.34) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SMN1; SMN2 646/4885TP53 759/4885RET 1/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SMN1; SMN2 646/4885TP53 759/4885RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.